Smith Kline & French Laboratories Limited

Boehringer Mannheim Gmbh

Smithkline Beckman Corporation

Robert A Slater

Anthony Maitland Roe

William J Coates

Edwin Michael Taylor

John C Emmett

Ernst-Christian Witte

Karlheinz Stegmeier

Brian H Warrington

Stephen P Breukelman

Graham J Durant

Robert John Ife

David G Cooper

Bernard Loev

Andrew D Gribble

Liesel Doerge

George D Meakins

The invention relates to phenylsulphonamidolkanoic acids which have thromboxane A.sub.2 receptor antagonist activity.

Biologically active compounds

The present invention concerns compounds of the formula: ##STR1## where R.sub.1 is an alkyl or alkenyl radical containing up to 6 carbon atoms, a cycloalkyl radical containing 3 to 7 carbon atoms, an aralkyl, aralkenyl or aryl radical in which the aryl radical or moiety can be substituted one or more times by halogen, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxyl, trifluoromethyl, cyano, nitro, amino, C.sub.1 -C.sub.6 -alkylamino, C.sub.2 -C.sub.12 -dialkylamino, C.sub.1 -C.sub.6 -acylamino, C.sub.1 -C.sub.16 -acyl, C.sub.1 -C.sub.6 -alkylsulphenyl, -sulphinyl or -sulphonyl or by azido, R.sub.2 is hydrogen atom or a C.sub.1 -C.sub.6 -alkyl, aralkyl, aralkenyl or acyl radical, A and B are saturated or unsaturated alkylene chains containing up to 10 carbon atoms which can be substituted one or more times by C.sub.1 -C.sub.3 -alkyl radicals, the sum of carbon atoms in chains A and B being at least 4 and at most 11, Q is an oxygen or sulphur atom, a sulphonyl or sulphinyl group or an amino group --N(R.sub.2)--, R.sub.2 having the same meaning as above, and Y is a free carboxylic acid group or a carboxylic acid ester, carboxylic acid amide, hydroxymethyl or tetrazolyl radical; the pharmacologically acceptable salts thereof and the optically active and E-Z isomers thereof, as well as mixtures thereof. These compounds are useful as they have an antagonistic action towards thromboxane A.sub.2 as well as against prostaglandin endoperoxide. They inhibit the aggregation of blood platelets and prevent the constriction of the smooth musculature as well as bronchoconstriction.

Substituted sulphonamides, pharmaceuticals thereof and methods of using

The invention relates to phenyl dihydropyridazinone derivatives that have utility as cardiac stimulants. A compound of the invention is 6-[4-(N.sup.3 -benzyl-N.sup.2 -cyanoguanidino)phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone.

Novel guanidino pyridazinones as cardiac stimulants

This invention relates to (isopropyl and tertiary butyl-amino-2-hydroxypropoxy)phenyl-3[2H]-pyridazinones which have .beta.-adrenoceptor antagonist activity.

5-phenyl-3[2H]-pyridazinone derivatives

The invention relates to a class of tetrahydroisoquinolinylalkanoic acids containing an aryl sulphonamide group which have activity as thromboxane A.sub.2 antagonists.

Pharmaceutically active compounds

Pharmaceutical compositions having .beta.-adrenoceptor antagonist

This invention relates to 5-(phenyl)-2(1H)-pyrazinones substituted in the 4-position of the phenyl ring by an amino or acylamino group. These compounds has inotropic activity. One specific compound is 5-(4-acetamidophenyl)-2(1H)-pyrazinone.

Heterocyclic compounds having inotropic activity

This invention relates to cyanoguanidine derivatives that have utility in the treatment of congestive heart failure. A specific compound of this invention is 6-[4-(N.sup.3 -methyl-N.sup.2 -cyanoguanidino)phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone.

6-(cyanoguanidinophenyl)pyridazinones as cardiac stimulants

This invention relates to dihydropyridazinone compounds having a cyclopropylmethoxyethyl group in the 6-substituent. These compounds are vasodilators and .beta.-adrenoceptor antagonists. A particular compound of the invention is 6-[4-[3-[2-hydroxy-3-[4-(2-(cyclopropylmethoxy) ethyl)phenoxy]propylamino]propionamido]phenyl]-5-methyl-4,5-dihydro-3 (2H)-pyridazinone.

Vasodilators and .beta.-adrenoceptor antagonists

This invention relates to 5-(4-substituted)phenylpyrazinone compounds which have positive inotropic and vasodilator activity. One such compound is 5-(4-carboxamidophenyl)pyrazin-2(1H)-one.

5-(4-substituted)phenyl-2-pyrazinones

This invention relates to 5-(phenyl)-2(1H)-pyrazinones substituted in the 4-position of the phenyl ring by an amino or acylamino group. These compounds have inotropic activity. One specific compound is 5-(4-acetamidophenyl)-2(1H)-pyrazinone.

5-(4-Amino or acylaminophenyl)-2(1H)-pyrazinones having inotropic

Substituted derivatives of 3-chloro-6-phenylpyridazine which are useful intermediates in the preparation of substituted phenylhydrazinopyridazines which have .beta.-adrenergic blocking and vasodilator activity.

3-Chloro-6-phenylpyridazine compounds

Substituted phenyl pyridazinethiones which are useful intermediates in the preparation of substituted phenylhydrazinopyridazines which have .beta.-adrenergic blocking and vasodilator activity.

Pyridazinethiones

The compounds are substituted hydrazinophthalazines which are active as .beta.-adrenergic blocking agents and as vasodilators. A specific compound of the invention is 5-(3-t-butylamino-2-hydroxypropoxy)-1-hydrazinophthalazine.

(3-Alkylamino-2-hydroxypropoxy)-1-hydrazinophthalazines

The compounds are 3-(3-(3-substituted amino-2-hydroxypropoxy)phenyl)-6-hydrazino pyridazines which have .beta.-adrenergic blocking and vasodilator activity.

Growing community of inventors

Letchworth, United Kingdom

Robert A Slater